Yishen Qutong Granules

Developed for: esophageal squamous cell carcinoma · small cell lung carcinoma
Investigated by: Henan Cancer Hospital · Shanxi Province Cancer Hospital · Anyang Tumor Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Changzhi People's Hospital · China-Japan Friendship Hospital
+16 more
· Chongqing University Cancer Hospital · Fudan University · Jilin Provincial Tumor Hospital · LI FENG · Liaoning Cancer Hospital & Institute · Mianyang Central Hospital · Shanghai Chest Hospital · Sichuan Cancer Hospital and Research Institute · The Affiliated Hospital of Qingdao University · The First Affiliated Hospital of Zhengzhou University · The First Hospital of Jilin University · The Second Affiliated Hospital of Harbin Medical University · Tianjin Medical University Cancer Institute and Hospital · Wuhan No.1 Hospital · Yuncheng Central Hospital · Zhejiang Cancer Hospital

202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT07390565	Feb → Dec 2026 expected	small cell lung carcinoma	LI FENG	Enrolling by invitation	No outcome recorded
—	NCT06863831	Aug 2024 → Oct 2025 overdue	esophageal squamous cell carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Enrolling by invitation	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Yishen Qutong Granules	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863831 ↗ 1 NCT07390565 ↗
Known as	Yishen Gu Kang Formula	“The Yishen Qutong Granules (Yishen Gu Kang Formula) were granted a patent prescription in 2017 (Patent No.: ZL201310582907.9).” NCT06863831 ↗
Modality	Traditional medicine (herbal / TCM)	“traditional Chinese medicine (TCM) for reinforcing healthy qi to strengthen the body and remove toxins” NCT06863831 ↗
Route	Oral	“the treatment group will be administered the patented TCM formula Yishen Qutong Granules orally” NCT06863831 ↗